Gearing up for potential commercialization of its lead program, ofatumumab, in chronic lymphocytic leukemia next year - and taking into account the current economic environment - Danish antibody firm Genmab A/S is cutting roughly 15 percent of its work force and halting work on a Phase III program in cutaneous T-cell lymphoma. (BioWorld Today)